Sudarshan Chemical Industries Limited announces an acquisition

The final cash consideration received was EUR 75.8 million for the completed sale of 100% of VP4 Frankfurt GmbH to Celanese on 2 November 2026 ^[1].

Using the reported EUR 127.5 million Heubach acquisition cost ^[2], the divestment reduces the effective cash acquisition outlay to:

EUR 127.5 million − EUR 75.8 million = EUR 51.7 million

Thus, the VP4 sale offsets approximately 59.5% of the original Heubach acquisition cost, calculated as EUR 75.8 million divided by EUR 127.5 million. This is an economic cash-cost bridge, not an accounting purchase-price allocation: it excludes any tax, transaction costs, debt assumed or repaid, and working-capital effects.

The final completion consideration is slightly below the EUR 76.5 million deal value announced when the agreement was signed ^[3]; therefore, the completed transaction value should be used for the net-cost calculation.

The carrying value of VP4 Frankfurt GmbH in Sudarshan Chemical’s consolidated financials cannot be confirmed from the cited disclosures. The company reported VP4’s net-worth contribution at EUR 5,670,674 as of 31 March 2026; this is not necessarily the same as its consolidated carrying amount, which could include acquisition-related fair-value adjustments or goodwill. ^[4]

No profit or loss from the divestment had been recognized in the P&L at the announcement stage. The definitive agreement was signed on 31 August 2026, but completion remained subject to customary conditions, with closing expected in approximately 2–3 months. ^[5]

Accordingly, the reported P&L impact at that point was nil/not yet recognized. The EUR 76.5 million sale consideration ^[5] should not be netted against the EUR 5.67 million net-worth figure to calculate a gain, because the latter is not confirmed as the consolidated carrying value.

Verdict: The VP4 Frankfurt transaction is a 100% equity sale of the subsidiary, not a separately itemized sale of named machinery, production lines or intellectual property. The buyer therefore acquires VP4 Frankfurt as a going concern, including the assets and rights held within that entity, but the completion filing does not identify any specific plant, equipment, patents, formulas or other IP transferred separately. Sudarshan completed the sale to Celanese US Holdings LLC on 2 November 2026. ^[1]

What is actually leaving Sudarshan

VP4 Frankfurt manufactured intermediates including Diketene and operated primarily as a tolling manufacturer for Nutrinova, a Celanese/Mitsui-related business; only a small portion of its output was used captively by Sudarshan. ^[6] Accordingly, the operational asset being exited is principally a German intermediate-manufacturing and tolling operation, rather than a core pigment plant.

The disclosure identifies the transaction as the sale of Sudarshan Germany Horizons’ entire stake in VP4 Frankfurt. ^[1] It does not provide a separate schedule of transferred manufacturing assets or IP. The most accurate conclusion is therefore:

• Manufacturing capability: VP4 Frankfurt’s Diketene/intermediate production operation moves with the sold subsidiary.
• Specific equipment or plant: not separately identified in the cited transaction disclosure.
• Intellectual property: no separately identified patents, formulations, process technology or licence transfer could be confirmed.
• Supply continuity: third-party industry coverage reports that Nutrinova will continue supplying Sudarshan with materials required for Sudarshan’s own operations after the sale. ^[7]

Effect on the European footprint

The exit removes one owned Frankfurt-based intermediate operation from Sudarshan’s European manufacturing footprint. It does not, on the evidence cited, represent a withdrawal from European pigments or a broad European manufacturing exit: VP4 was described as a non-core, largely tolling business acquired through Heubach, while the strategic rationale was to sharpen focus on pigments and colourants. ^[6]

Relative to the Heubach integration and capacity-rationalization agenda, the transaction is best viewed as the execution of a portfolio-clean-up measure already associated with the acquired business: VP4 was described as having been earmarked for divestment. ^[8] However, the cited material does not provide the original acquisition-era site-by-site capacity plan or quantify how much European pigment capacity was intended to be removed. It therefore cannot establish whether the VP4 sale is incremental to, or fully included within, those earlier rationalization targets.

Implication: Sudarshan’s European footprint becomes narrower and more pigment-centric, with lower exposure to non-core intermediate manufacturing and tolling economics. The strategic footprint reduction appears targeted rather than broad-based; the key unresolved issue is the extent to which the remaining Heubach European assets still require further consolidation.